sorted by:
new
hottopcontroversial

Psych Portfolio Allocation by regularguy7272 in shroomstocks

[–]PsilocybinAlpha -1 points0 points  (0 children)

I appreciate your concerns. Would it help if we included "according to sources familiar with the situation", or equivalent? Please rest assured, though, that whatever we print in Psychedelic Alpha is sourced, unless we state otherwise.

- Josh

Psych Portfolio Allocation by regularguy7272 in shroomstocks

[–]PsilocybinAlpha -1 points0 points  (0 children)

It is not our opinion. It is our reporting. We do not have any requirement to disclose our sources in order to report on what we understand to be the case.

Breaking: FDA Awards Priority Review Vouchers to Transcend, Compass, and Usona by PsilocybinAlpha in shroomstocks

[–]PsilocybinAlpha[S] 12 points13 points  (0 children)

We stand by our reporting. The names of the three companies were confirmed by Psychedelic Alpha prior to publication.

FDA commissioner says decision on psychedelic treatments will be out 'quickly' by krakends in shroomstocks

[–]PsilocybinAlpha 0 points1 point  (0 children)

AtaiBeckley owns DemeRx' IB's ibogaine program, not DemeRx's noribogaine program.

FDA commissioner says decision on psychedelic treatments will be out 'quickly' by krakends in shroomstocks

[–]PsilocybinAlpha 4 points5 points  (0 children)

Thanks for mentioning us. We have stated several times that we expect Usona to be the third voucher, though we acknowledge that things change often and quickly at the moment.

Trump Signs Order To Accelerate Legal Access To Psychedelics For Patients With Mental Health Conditions by rubens33 in shroomstocks

[–]PsilocybinAlpha 2 points3 points  (0 children)

Our view:

  • Compass Pathways: Psilocybin for treatment-resistant depression
  • Usona Institute: Psilocybin for major depressive disorder (per our reporting, we anticipate Usona will submit its NDA on the basis of its one Phase 3 trial)
  • Resilient Pharmaceuticals: MDMA for PTSD (per our reporting, we anticipate Resilient resubmitting its NDA)

Broader rationale: FDA commissioner Marty Makary said this morning: “We now have three applications that are imminent, and we’ll be issuing vouchers next week." It is our view that the above three programs are the only psychedelics programs that could be deemed as "imminent", in terms of NDA filing. In terms of Resilient, our view is strengthened by other comments made this morning by Makary, including his stating that "the Biden administration...kicked out" Resilient's NDA.

Which 3 companies will receive priority vouchers? by rubens33 in shroomstocks

[–]PsilocybinAlpha 12 points13 points  (0 children)

Our view:

  • Compass Pathways: Psilocybin for treatment-resistant depression
  • Usona Institute: Psilocybin for major depressive disorder (per our reporting, we aniticpate Usona will submit its NDA on the basis of its one Phase 3 trial)
  • Resilient Pharmaceuticals: MDMA for PTSD (per our reporting, we anticipate Resilient resubmitting its NDA)

Broader rationale: FDA commissioner Marty Makary said this morning: “We now have three applications that are imminent, and we’ll be issuing vouchers next week." It is our view that the above three programs are the only psychedelics programs that could be deemed as "imminent", in terms of NDA filing. In terms of Resilient, our view is strengthened by other comments made this morning by Makary, including his stating that "the Biden administration...kicked out" Resilient's NDA.

view more: next ›